BioNTech SE (ETR:22UA)

Germany flag Germany · Delayed Price · Currency is EUR
89.45
-4.60 (-4.89%)
Last updated: May 5, 2025
4.01%
Market Cap 21.42B
Revenue (ttm) 2.75B
Net Income (ttm) -766.00M
Shares Out n/a
EPS (ttm) -3.19
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 143
Average Volume 1,712
Open 91.85
Previous Close 94.05
Day's Range 89.45 - 92.65
52-Week Range 69.70 - 124.60
Beta 1.08
RSI 46.72
Earnings Date May 5, 2025

About BioNTech SE

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in ph... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 6,772
Stock Exchange Deutsche Börse Xetra
Ticker Symbol 22UA
Full Company Profile

Financial Performance

Financial Statements

News

BioNTech GAAP EPS of -€1.73, revenue of €182.8M; reaffirms FY25 outlook

BioNTech press release (BNTX): Q1 GAAP EPS of -€1.73. Revenue of €182.8M (-2.6% Y/Y). Cash and cash equivalents plus security investments as of March 31, 2025, reached €15,854.4 million,

1 day ago - Seeking Alpha

BioNTech Announces First Quarter 2025 Financial Results and Corporate Update

Continued oncology pipeline advancement with a strategic focus on two priority pan-tumor programs: next-generation immunomodulator BNT327, a bispecific antibody targeting PD-L1 and VEGF-A 1 , and mRNA...

1 day ago - GlobeNewsWire

BioNTech says Novartis executive Zapata-Gomez to become CFO

German COVID-19 vaccine maker BioNTech said on Monday that Ramon Zapata-Gomez will become its new finance chief from July 1.

1 day ago - Reuters

BioNTech Announces Appointment of Ramón Zapata to Management Board as Chief Financial Officer

Mainz, Germany, May 5, 2025 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that the Supervisory Board has appointed Ramón Zapata-Gomez to the Management Boa...

1 day ago - GlobeNewsWire

Earnings Scheduled For May 5, 2025

Companies Reporting Before The Bell • Recursion Pharmaceuticals (NASDAQ: RXRX) is likely to report quarterly loss at $0.52 per share on revenue of $18.08 million. • Freshpet (NASDAQ: FRPT) is estima...

1 day ago - Benzinga

BioNTech Q1 2025 Earnings Preview

4 days ago - Seeking Alpha

Prediction: 1 Biotech Stock That Could Surpass Pfizer by 2030

Pfizer (NYSE:PFE) is a global pharmaceutical giant that has long been a cornerstone of medical innovation and today boasts a $128 billion market cap. Renowned for its blockbuster drugs like Lipitor an...

12 days ago - 24/7 Wall street

BioNTech to Present Clinical and Preclinical Data Across mRNA and Next-Generation Immuno-Oncology Priority Programs at AACR 2025

MAINZ, Germany, April 24, 2025 -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present data for selected assets from its diversified oncology pipeline, including mRNA cancer immunother...

12 days ago - GlobeNewsWire

BioNTech Surges On Summit's Coattails. But Can They Take On Merck?

BioNTech stock rocketed Wednesday after rival Summit Therapeutics unveiled promising results for a novel approach to lung cancer treatment.

13 days ago - Investor's Business Daily

BioNTech to Report First Quarter 2025 Financial Results and Corporate Update on May 5, 2025

MAINZ, Germany, April 22, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2025 on Monday, May 5, 2025. Additi...

14 days ago - Wallstreet:Online

BioNTech to Report First Quarter 2025 Financial Results and Corporate Update on May 5, 2025

MAINZ, Germany, April 22, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2025 on Monday, May 5, 2025. Additi...

14 days ago - GlobeNewsWire

Vaccine stocks fall following FDA resignation

Dr. Kavita Patel joins 'Fast Money' to talk the impact of FDA and HHS changes on vaccines, public health policy, and more.

5 weeks ago - CNBC Television

Vaccine stocks tumble: Moderna, Novavax, Pfizer fall after top FDA official resigns over RFK Jr. anti-vax views

Stocks of major vaccine makers dropped on Monday after the Food and Drug Administration's (FDA) top vaccine official Dr. Peter Marks resigned, citing conflicts with Health and Human Services (HHS) Sec...

5 weeks ago - Fast Company

Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul

Shares of U.S. drugmakers fell on Monday after reports that the Food and Drug Administration's top vaccine official was forced to resign, the most high-profile exit at the regulator as the Trump admin...

5 weeks ago - New York Post

Vaccine stocks fall after key FDA official resigns in protest of RFK Jr.

Shares of vaccine makers Moderna and Novavax, along with a range of other biotech companies, fell after the resignation of key FDA official Peter Marks. Marks stepped down in protest of Health and Hum...

5 weeks ago - CNBC

Biotech stocks tumble on reports FDA's top vaccine regulator to leave

Shares of U.S. biotech companies fell as much as 10% premarket on Monday following reports that a top vaccine official at the U.S. Food and Drug Administration had resigned, fanning worries over slowe...

5 weeks ago - Reuters

CureVac Shares Rise on Patent Confirmation Amid BioNTech Lawsuit

Shares of CureVac climbed after the European Patent Office confirmed the validity of a patent that has been the subject of a lawsuit filed by BioNTech.

5 weeks ago - Market Watch

European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps

CureVac N.V. (NASDAQ: CVAC) on Thursday said the European Patent Office (EPO) confirmed the validity of CureVac’s European patent EP 3 708 668 B1 subject to amendments to specify the scope of protect...

5 weeks ago - Benzinga

CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE

European Patent Office largely dismisses opposition filed by BioNTech SE in April 2023 challenging validity of EP 3 708 668 B1 and maintains the patent in amended formA hearing on infringement of EP 3...

5 weeks ago - Wallstreet:Online

EQS-News: CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE

Issuer: CureVac / Key word(s): Patent CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE 27.03.2025 / 21:05 CET/CEST The issuer is solely respons...

5 weeks ago - Wallstreet:Online

Looking At BioNTech's Recent Unusual Options Activity

Deep-pocketed investors have adopted a bearish approach towards BioNTech (NASDAQ: BNTX), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveile...

5 weeks ago - Benzinga

Refractory Metastatic Melanoma Pipeline Report 2025, with Focus on BioNTech SE, Y-mAbs and Therapeutics Seagen

Dublin, March 20, 2025 (GLOBE NEWSWIRE) -- The "Refractory Metastatic Melanoma - Pipeline Insight, 2025" clinical trials has been added to ResearchAndMarkets.com's offering. The report provides compre...

6 weeks ago - GlobeNewsWire